Abstract
BackgroundAN4005 is an orally available, small-molecule programmed cell death ligand 1 (PD-L1) inhibitor that demonstrates antitumor activity by blocking the interaction between PD-L1 and programmed cell death-1 (PD-1). In animal...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
